tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Bicara Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe FlyBicara Therapeutics initiated with an Overweight at Piper Sandler
1M ago
Bicara Therapeutics Reports Q2 2025 Results and Progress
Premium
Company Announcements
Bicara Therapeutics Reports Q2 2025 Results and Progress
2M ago
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
Premium
Ratings
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
2M ago
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
PremiumRatingsPromising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
4M ago
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating
Premium
Ratings
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating
4M ago
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
4M ago
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
PremiumRatingsPromising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
4M ago
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
Premium
Ratings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
4M ago
Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
Premium
The Fly
Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100